1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63A5C13CDEEC053A2852569670059B5B3
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-building-pharmaceutical-brand-through-continuing-education?opendocument
18
19opendocument
2098.80.143.34
21
22
23
24/bestp/domrep.nsf
25DB




» Products & Services » » Brand Management and Product Leadership » Branding and Identity

Building Pharmaceutical Brand through Continuing Education -- An Executive Summary

DB Image

ID: 3691


Features:

Graphics


Words: 2,137


Published: Pre-2019


Delivery Format: Online


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Project Background
Best Practices, LLC undertook this benchmarking project in order to identify
the effective and innovative practices that leading pharmaceutical
manufacturers have used to deliver education to health care providers. The
findings will support any pharma company’s efforts to build stronger customer
relationships and ultimately drive market share growth. Analysis of benchmark
data also provides a deeper understanding of top companies’ organizational and
team structure -- and how corporate cultures come to perceive health care
education as a strategic tool in today’s competitive marketplace.

The insights and best practices showcased in this report are distilled from
lessons learned interviews with executives who have extensive experience in
designing and delivering HCE programs. While this combined body of knowledge
concerning health care education excellence is far greater than what any single
company in the benchmark class has currently implemented, these insights
provide a valuable operational compass to guide your efforts to create a
best-in-class HCE system in the pharmaceutical industry.

Project Methodology
The project team conducted in-depth interviews with six pharmaceutical
companies ...

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device


Companies Profiled:
Eli Lilly; Novartis; Hoechst Marion Roussel; Bayer; AstraZeneca; DuPont Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.